Melanoma
Conditions
Keywords
Melanoma, Stage IV, Phase II
Brief summary
The trial is designed as a phase II evaluation of the effect of CY-503 on progression free survival (PFS) in patients with stage IV malignant melanoma after failure of prior therapy. The aim of the study is at least a rate of 25% (PFS \>/= 3 months).
Interventions
DRUGCY-503
solution for subcutaneous injection, 350 ng twice weekly
Sponsors
Cytavis Biopharma GmbH
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed, unresectable, Stage IV metastatic melanoma * Failure of prior chemotherapy and / or immunotherapy based regimen * Measurable disease (based on RECIST criteria) * Males and females of at least 18 years of age * Women of reproductive potential (defined as being \<1 year post-menopausal) must have a negative pregnancy test within 3 days prior to randomization; and men and women of reproductive potential must agree to practice an effective method of avoiding pregnancy * Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1. * Life expectancy of at least 3 months * WBC ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3, platelet count ≥100,000/mm3 * Bilirubin ≤ 1.5 mg/dL (25.65 μmol/L) (unless due to Gilbert's syndrome in which case the bilirubin should be ≤3.5 mg/dL (59.86 μmol/L)), aspartate transaminase (AST)/alanine transaminase (ALT) ≤ 3 × upper limit of normal (ULN); hepatic alkaline phosphatase ≤ 3.0 × ULN * LDH ≤ 2.5 upper limit of normal (ULN) * Serum creatinine ≤ 1.5 mg/dL (132.60 μmol/L), proteinuria \< 2.0 g/24 hr urine * Patients who have had prior treatment with adjuvant or palliative immunotherapy are eligible provided that therapy ended at least 1 month prior to randomization and all treatment-related toxicities have resolved * Patients with bone metastasis should be evaluated by the investigator and prior treatment should be finished at least 1 month prior to randomization * Prior radiotherapy (for palliative care only) is allowed provided there is measurable/evaluable disease outside of the radiation field and all radiation-related toxicities have resolved; if there is only one measurable lesion it may not have been irradiated unless subsequent progression has been documented * Patients who had prior major surgery are eligible if at least 4 weeks have passed since their surgery and all surgical wounds have healed prior to randomization and at least one measurable tumor is present * All toxicities related to prior adjuvant therapy must have resolved * Written informed consent
Exclusion criteria
* Pregnancy or nursing * Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for treatment of cancer * Current or planned participation in a research protocol * Received an investigational agent within 4 weeks prior to randomization * Brain metastases or primary brain tumors, symptomatic pleural effusion or ascites requiring paracentesis * Ocular melanoma * History of prior malignancies within the past 5 years other than non-melanomatous skin cancers that have been controlled, carcinoma in situ of the cervix, T1a or b prostate cancer noted incidentally during a transurethral resection of prostate (TURP) with prostate-specific antigen (PSA) values within normal limits since TURP, or superficial bladder cancer * Any evidence of or history elicited by the investigator of symptomatic cerebrovascular events within 6 months prior to randomization; or any history or evidence of pulmonary embolism or thrombophlebitis requiring anticoagulant therapy * Any current evidence of hematemesis, melena, hematochezia, or gross hematuria * Elective surgery planned during the study period through 30 days after the last dose of CY-503 * History of hypersensitivity to previously administered mistletoe * Prior therapy with mistletoe * History of primary immunodeficiency * Known human immunodeficiency virus (HIV) or known active viral hepatic infections * Prior treatment with CY-503 * A general medical or psychological condition or behaviour in the opinion of the investigator, might not permit the patient to complete the study or sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor assessment by CT and MRT | each 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Immunological response (e.g. measurement of cytokines in serum) | each 4 weeks |
| Assessment of quality of life using a standardized questionnaire | each 4 weeks |
Countries
Germany
Outcome results
None listed